INTUITT-NF2
INTUITT-NF2 is a rolling trial for people with the inherited condition NF2, who grow many benign tumours of the nerves and brain lining; its first drug, brigatinib, shrank a share of tumours, slowed the growth of all types and improved hearing in a third of affected ears, which is the evidence behind offering it for these tumours.
Overview
INTUITT-NF2 is an investigator-led adaptive platform trial for adults and adolescents with NF2-related schwannomatosis and progressive target tumours, run from Massachusetts General Hospital with the Children's Tumor Foundation and drug supply from Takeda and Incyte. Sub-studies test one drug at a time against a shared design; brigatinib (a kinase inhibitor identified by preclinical screening) was the first, followed by neratinib and retifanlimab with bevacizumab. The primary endpoint of each sub-study is the radiographic response rate.
In the brigatinib sub-study 40 patients with 10 vestibular schwannomas, 8 non-vestibular schwannomas, 20 meningiomas and 2 ependymomas as target tumours were treated; 10 percent of target tumours and 23 percent of all tumours responded, annualised growth rates fell for every tumour type, hearing improved in 35 percent of eligible ears and there were no grade 4 or 5 treatment-related events. The corpus's vestibular schwannoma page cites INTUITT-NF2 as the evidence for brigatinib.
- 10 out of 100 people had their tumour shrink with Brigatinib.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- 23 out of 100 people had their tumour shrink with Brigatinib.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- 35 out of 100 people reached this endpoint with Brigatinib.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- These results apply to the people the trial enrolled: NF2-related schwannomatosis with progressive vestibular or non-vestibular schwannomas, meningiomas or ependymomas: an adaptive platform trial testing targeted drugs in sub-studies (brigatinib, closed; neratinib; retifanlimab with bevacizumab), with radiographic response as the primary endpoint. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
109 enrolled.
95% CI 3 to 24; median follow-up 10.4 months
Source95% CI 16 to 30
Source95% CI 20 to 53
SourceSimilar pages
not linked directly; found by shared links- TrialPOD1UM-303/InterAACT-2
Shares Retifanlimab, Incyte and the tag soc-trials.
- TrialCOMFORT-I
Shares Incyte, Small-molecule kinase inhibitors and the tag soc-trials.
- TrialAALL1521
Shares Incyte, Small-molecule kinase inhibitors and the tag soc-trials.
- TrialNOA-08
Shares Brain and spinal cord tumours (all types) and the tag soc-trials.
- TrialACNS1422
Shares Brain and spinal cord tumours (all types) and the tag soc-trials.
- TrialACNS0121
Shares Brain and spinal cord tumours (all types) and the tag soc-trials.
- TrialACNS1123
Shares Brain and spinal cord tumours (all types) and the tag soc-trials.
- TrialACNS0122
Shares Brain and spinal cord tumours (all types) and the tag soc-trials.